1. Mehta J. Allogeneic hematopoietic stem cell transplantation in myeloma. In: Mehta J, Singhal S, eds. Myeloma. London, UK: Martin Dunitz; 2002:349–365.
2. Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S, eds. Myeloma. London, UK: Martin Dunitz; 2002:327–347.
3. Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Mehta J. “Discontinuous complete remission”: a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time [abstract].Blood. 2001;98:166a.
4. Powles R, Sirohi B, Treleaven J, et al. Continued first complete remission in multiple myeloma for over 10 years: a series of “operationally cured” patients [abstract].Blood. 2000;96(suppl 1):515a.
5. Zwingenberger K, Wnendt, S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations.J Inflamm. 1995;46:177–211.